C3aR Antibody (74): sc-53785

C3aR Antibody (74) is a mouse monoclonal IgG1 antibody that detects C3aR in mouse and rat samples through applications such as immunofluorescence (IF) and flow cytometry (FCM). C3aR, or complement component 3a receptor, plays a crucial role in the immune response by mediating the effects of the anaphylatoxin C3a, which is released during complement activation. C3aR is primarily located on the surface of myeloid leukocytes, as well as in the brain and activated B-lymphocytes, highlighting its importance in both innate and adaptive immunity. The binding of C3a to C3aR triggers a cascade of pro-inflammatory events, including cellular degranulation and cytokine release, which are vital for orchestrating an effective immune response against pathogens. C3aR expression in the central nervous system suggests potential involvement in neuroinflammatory processes, making C3aR a significant target for research in conditions such as asthma and bacterial meningitis. C3aR undergoes rapid phosphorylation and internalization upon activation, which regulates signaling and ensures appropriate immune response modulation. Anti-C3aR antibody (74) serves as an essential tool for researchers studying the complexities of immune signaling and inflammation.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

C3aR Antibody (74) References:

1. The Complement Receptors C3aR and C5aR Are a New Class of Immune Checkpoint Receptor in Cancer Immunotherapy.  |  Wang, Y., et al. 2019. Front Immunol. 10: 1574. PMID: 31379815
2. Complement activation promoted by the lectin pathway mediates C3aR-dependent sarcoma progression and immunosuppression.  |  Magrini, E., et al. 2021. Nat Cancer. 2: 218-232. PMID: 34505065
3. Complement C3a Receptor (C3aR) Mediates Vascular Dysfunction, Hippocampal Pathology, and Cognitive Impairment in a Mouse Model of VCID.  |  Bhatia, K., et al. 2022. Transl Stroke Res. 13: 816-829. PMID: 35258803
4. C3aR costimulation enhances the antitumor efficacy of CAR-T cell therapy through Th17 expansion and memory T cell induction.  |  Lai, P., et al. 2022. J Hematol Oncol. 15: 68. PMID: 35597971
5. The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML.  |  von Palffy, S., et al. 2023. Blood Adv. 7: 1204-1218. PMID: 36383712
6. C3aR in the medial prefrontal cortex modulates the susceptibility to LPS-induced depressive-like behaviors through glutamatergic neuronal excitability.  |  Sun, R., et al. 2024. Prog Neurobiol. 236: 102614. PMID: 38641040
7. Complement C3aR signaling: Immune and metabolic modulation and its impact on Alzheimer's disease.  |  Gedam, M. and Zheng, H. 2024. Eur J Immunol. 54: e2350815. PMID: 38778507
8. Complement C3a/C3aR inhibition alleviates the formation of aortic aneurysm in Marfan syndrome mice.  |  Zhang, F., et al. 2024. BMC Cardiovasc Disord. 24: 417. PMID: 39127656
9. Complement 3a induces the synapse loss via C3aR in mitochondria-dependent NLRP3 activating mechanisms during the development and progression of Alzheimer's disease.  |  Ge, TQ., et al. 2024. Neurosci Biobehav Rev. 165: 105868. PMID: 39218048
10. Astrocyte-neuron communication through the complement C3-C3aR pathway in Parkinson's disease.  |  Chi, X., et al. 2025. Brain Behav Immun. 123: 229-243. PMID: 39288893

The preferred C3aR antibody is C3aR Antibody (D-12): sc-133172.